160 related articles for article (PubMed ID: 38174531)
1. Comparative evaluation of efficacy and tolerability of apremilast and methotrexate in patients of moderate-to-severe palmoplantar psoriasis: A randomized, parallel, open-label clinical trial.
Wagh M; Mukhi J; Sontakke S; Dhok A; Turankar A; Kalikar M
Indian J Pharmacol; 2023; 55(6):356-362. PubMed ID: 38174531
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.
Kt S; Thakur V; Narang T; Dogra S; Handa S
Am J Clin Dermatol; 2021 May; 22(3):415-423. PubMed ID: 33712987
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis: A prospective, randomised, assessor-blinded, comparative study.
Hassanandani T; Panda M; Jena AK; Raj C
Indian J Dermatol Venereol Leprol; 2023; 89(2):213-220. PubMed ID: 35841363
[TBL] [Abstract][Full Text] [Related]
4. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
Bissonnette R; Haydey R; Rosoph LA; Lynde CW; Bukhalo M; Fowler JF; Delorme I; Gagné-Henley A; Gooderham M; Poulin Y; Barber K; Jenkin P; Landells I; Pariser DM
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):403-410. PubMed ID: 29055155
[TBL] [Abstract][Full Text] [Related]
5. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
[TBL] [Abstract][Full Text] [Related]
6. Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis.
Spencer RK; Elhage KG; Jin JQ; Davis MS; Hakimi M; Bhutani T; Liao W
Dermatol Ther (Heidelb); 2023 Feb; 13(2):437-451. PubMed ID: 36609960
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
Stein Gold L; Papp K; Pariser D; Green L; Bhatia N; Sofen H; Albrecht L; Gooderham M; Chen M; Paris M; Wang Y; Callis Duffin K
J Am Acad Dermatol; 2022 Jan; 86(1):77-85. PubMed ID: 34343599
[TBL] [Abstract][Full Text] [Related]
9. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Del Alcázar E; Suárez-Pérez JA; Armesto S; Rivera R; Herrera-Acosta E; Herranz P; Martín I; Montesinos E; Hospital M; Vilarrasa E; Ferran M; Ruiz-Villaverde R; Sahuquillo-Torralba A; Ruiz-Genao DP; Pérez-Barrio S; Muñoz C; Llamas M; Valentí F; Mitxelena MJ; López-Ferrer A; Carretero G; Vidal D; Mollet J; Belinchón I; Carrascosa JM
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2821-2829. PubMed ID: 32271966
[TBL] [Abstract][Full Text] [Related]
11. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Wilsmann-Theis D; Kromer C; Gerdes S; Linker C; Magnolo N; Sabat R; Reich K; Mössner R
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2045-2050. PubMed ID: 34077577
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Terui T; Okubo Y; Kobayashi S; Sano S; Morita A; Imafuku S; Tada Y; Abe M; Yaguchi M; Uehara N; Handa T; Tanaka M; Zhang W; Paris M; Murakami M
Am J Clin Dermatol; 2023 Sep; 24(5):837-847. PubMed ID: 37233897
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
Merola JF; Parish LC; Guenther L; Lynde C; Lacour JP; Staubach P; Cheng S; Paris M; Picard H; Deignan C; Jardon S; Chen M; Papp KA
J Am Acad Dermatol; 2024 Mar; 90(3):485-493. PubMed ID: 37852306
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study.
Janagond AB; Kanwar AJ; Handa S
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e384-9. PubMed ID: 23066720
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
Ighani A; Georgakopoulos JR; Zhou LL; Walsh S; Shear N; Yeung J
J Cutan Med Surg; 2018; 22(3):290-296. PubMed ID: 29373924
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
